Risk For Below Knee Amputations With Canagliflozin Vs Other Antihyperglycemic Agents | Latest News RSS feed

Risk For Below Knee Amputations With Canagliflozin Vs Other Antihyperglycemic Agents - Latest News


Johnson & Johnson : - No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA Compared to Other Diabetes Medications

which found no increased risk of below-knee lower extremity (BKLE) amputation with INVOKANA (canagliflozin) compared to other sodium glucose cotransporter 2 inhibitors (SGLT2i) or non-SGLT2i anti-hype... read more

INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events

Comparable effects were also observed for other CV and renal ... had at least two CV risk factors. The study assessed the safety of canagliflozin relative to placebo in patients receiving specific com... read more

Johnson & Johnson : Janssen Pharmaceutical Companies - Real-World Study of More than 700,000 People with Type 2 Diabetes

which found no increased risk of below-knee lower extremity (BKLE) amputation with INVOKANA (canagliflozin) compared to other sodium glucose cotransporter 2 inhibitors (SGLT2i) or non-SGLT2i anti-hype... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us